Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.69 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.69 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.69 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.69 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.69 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.69 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.69 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 5/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451347 | 0.90 | TGFBR1 (0.67) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL415033 | 0.90 | TGFBR1 (0.62) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL5233695 | 0.89 | TGFBR1 (0.72) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL5240199 | 0.89 | TGFBR1 (0.63) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL373668 | 0.87 | TGFBR1 (1.00) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL413271 | 0.86 | TGFBR1 (0.92) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL451345 | 0.85 | TGFBR1 (0.71) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL16695915 | 0.84 | TGFBR1 (0.81) | TGFBR1MAPK14TGFBR2KDRGAK | |
| SCHEMBL413598 | 0.84 | TGFBR1 (0.69) | TGFBR1MAPK14TGFBR2THRB | |
| SCHEMBL15678350 | 0.83 | TGFBR1 (0.87) | TGFBR1MAPK14TGFBR2KDRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | claimed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | claimed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2012138945-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PYRAZOLE DERIVATIVE INHIBITORS OF TGF - BETA | AESTUS THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 546/4885TGFBR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.